ArticleMonoclonal antibodies in immunodiagnosis and immunotherapy2013
Preparation and characterization of monoclonal antibodies against VSTM1.
Article in Monoclonal antibodies in immunodiagnosis and immunotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 6 citations in OpenAlex.
- Multiple datasets to explore the molecular mechanism of sepsis.BMC genomic data · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VSTM1 (V-set and transmembrane domain containing 1) is a novel membrane molecule identified from immunogenomics, which has two main isoforms, VSTM1-v1 and VSTM1-v2. VSTM1-v1 is a type I transmembrane protein, and VSTM1-v2 is a classical secretory protein, lacking only the transmembrane domain compared with VSTM1-v1. This study was designed to generate VSTM1-specific monoclonal antibodies (MAbs) for further exploration of its expression and function. Mice were immunized with two recombinant prokaryotic proteins of GST-VSTM1-v2 and VSTM1-v2 without any tag. Hybridomas were generated by the fusion of the splenocytes to Sp2/0 myeloma cells. Three hybridoma cell lines (2C11, 6E11, and 7A8) stable in secreting anti-VSTM1 MAb were obtained and further characterized. All three MAbs were IgG2b isotype and effective in detecting the overexpressed VSTM1 in both Western blot and flow cytometry assays, while recognizing the endogenous VSTM1 in Western blot analysis only. These MAbs could be helpful in the basic study of VSTM1 and in revealing the interesting conformation difference between the overexpressed and endogenous proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.